Niemann-Pick C1-like 1 (NPC1L1) is a target for ezetimibe, a drug that blocks intestinal cholesterol absorption. A new study by Ge et al. (2008) in this issue of Cell Metabolism shows that non-lipoprotein-bound cholesterol induces endocytosis of NPC1L1 and that ezetimibe blocks the internalization of the NPC1L1/cholesterol complex. The in vivo significance of these findings is discussed
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is ...
SummaryTreatment of dyslipidemia is important for the primary and secondary prevention of cardiovasc...
Ezetimibe is a relatively new drug that inhibits the absorption of dietary cholesterol in the small ...
SummaryNiemann-Pick C1-like 1 (NPC1L1) is a polytopic transmembrane protein that plays a critical ro...
© 2016 Bentham Science Publishers. Circulating levels of cholesterol are derived from either endogen...
Niemann-Pick C1-Like 1 (NPC1L1) is highly expressed in the small intestine across mammalian species ...
Absorption of dietary cholesterol in the proximal region of the intestine is mediated by Niemann-Pic...
The cholesterol absorption inhibitor ezetimibe can significantly reduce plasma cholesterol concentra...
The impact of low density lipoprotein (LDL) cholesterol levels on cardiovascular risk has been exten...
Background - Strategies to reduce LDL-cholesterol involve reductions in cholesterol synthesis or abs...
Ezetimibe (EZE) and glucuronidated EZE (EZE-Glu) differentially target Niemann-Pick C1-like 1 (NPC1L...
Polytopic transmembrane protein, Niemann-Pick C1-Like 1 (NPC1L1) is localized at the apical membrane...
AbstractThe polytopic transmembrane protein, Niemann–Pick C1-Like 1 (NPC1L1), is enriched in the api...
Ezetimibe is the first in class 2-azetidinone that decreases plasma cholesterol by blocking intestin...
Niemann-Pick C1-Like 1 (NPC1-L1), as its name indicates, was identified in 2000 as a homolog of NPC1...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is ...
SummaryTreatment of dyslipidemia is important for the primary and secondary prevention of cardiovasc...
Ezetimibe is a relatively new drug that inhibits the absorption of dietary cholesterol in the small ...
SummaryNiemann-Pick C1-like 1 (NPC1L1) is a polytopic transmembrane protein that plays a critical ro...
© 2016 Bentham Science Publishers. Circulating levels of cholesterol are derived from either endogen...
Niemann-Pick C1-Like 1 (NPC1L1) is highly expressed in the small intestine across mammalian species ...
Absorption of dietary cholesterol in the proximal region of the intestine is mediated by Niemann-Pic...
The cholesterol absorption inhibitor ezetimibe can significantly reduce plasma cholesterol concentra...
The impact of low density lipoprotein (LDL) cholesterol levels on cardiovascular risk has been exten...
Background - Strategies to reduce LDL-cholesterol involve reductions in cholesterol synthesis or abs...
Ezetimibe (EZE) and glucuronidated EZE (EZE-Glu) differentially target Niemann-Pick C1-like 1 (NPC1L...
Polytopic transmembrane protein, Niemann-Pick C1-Like 1 (NPC1L1) is localized at the apical membrane...
AbstractThe polytopic transmembrane protein, Niemann–Pick C1-Like 1 (NPC1L1), is enriched in the api...
Ezetimibe is the first in class 2-azetidinone that decreases plasma cholesterol by blocking intestin...
Niemann-Pick C1-Like 1 (NPC1-L1), as its name indicates, was identified in 2000 as a homolog of NPC1...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is ...
SummaryTreatment of dyslipidemia is important for the primary and secondary prevention of cardiovasc...
Ezetimibe is a relatively new drug that inhibits the absorption of dietary cholesterol in the small ...
DOI
Add to ORKG